Pharmafile Logo
Pharmafocus logo
Advanced Search
novartis_outside_1

Novartis’ arthritis therapy shows no efficacy in hospitalised COVID-19 patients

November 6, 2020
Medical Communications, Research and Development COVID-19, Novatis, canakinumab

Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to …

News
top_10_image_2

Pharmafile.com’s weekly COVID-19 news round-up

November 6, 2020
Medical Communications COVID, COVID-19, EC, FDA, coronavirus

The top ten news stories this week focus on regulatory approvals as the European Commission has approved GlaxoSmithKline’s Zeljula as …

News
shutterstock_2

Australia secures a further 50m COVID-19 vaccine doses from Novavax and Pfizer/BioNTech

November 5, 2020
Manufacturing and Production Australia, COVID-19, Vaccine

Two more COVID-19 vaccine distribution deals have been signed by the Australian Government, reserving a further 50 million doses to …

News
fda_21_4_1_0

Biogen’s Alzheimer’s drug expected to be approved by the FDA after successful late-stage trial

November 5, 2020
Business Services

Biogen’s Alzheimer’s drug aducanumab is on track to be approved by the FDA after a successful late-stage clinical trial.  The …

News

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

News
psilocybe_semilanceata_6514

Psilocybin has substantial antidepressant effects according to a new study

November 5, 2020
Business Services

Psilocybin has substantial and enduring antidepressant effects, according to a new study conducted by a team at John Hopkins University.  …

News
1199px-american_mink_geograph

Denmark set to cull mink population after mutated strain of COVID-19 spreads to humans

November 5, 2020
Business Services

Denmark is set to cull its 17 million mink population after it was found a mutation of coronavirus in the …

News
tt

How the US election could affect the pharmaceutical industry

November 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Donald Trump, Joe Biden, Trump, US, US election 2020, pharma

The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of …

Feature
covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

November 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK, US, remdesivir

As European nations fall one by one back into lockdown, hopes weigh heavily on a vaccine to pave a path …

News
celltrion1

Celltrion’s Humira biosimilar is comparable in treating rheumatoid arthritis

November 4, 2020
Research and Development Humira, biosimilar, celltrion, rheumatoid arthritis

Celltrion has revealed new Phase 3 data demonstrating that its high concentration (100mg/mL) and citrate-free biosimilar CT-P17 proved comparable to …

News
s_pills

Nostrum Laboratories recalls metformin tablets over safety concerns

November 4, 2020
Manufacturing and Production, Research and Development Nostrum laboratories, metformin, recall

Missouri-based Nostrum Laboratories has issued a product recall of its type 2 diabetes drug metformin to the FDA over concerns …

News

J&J’s appeal shot down over $2.12m payment due to allegedly carcinogenic talc products

November 4, 2020
Research and Development, Sales and Marketing J&J, JJ, baby powder, ovarian cancer, talc

Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …

News

Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis

November 4, 2020
Research and Development BMS, deucravacitinib, plaque psoriasis

Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …

News
regeneron

Regeneron halts Phase 1 study into ultra-rare disease due to patient deaths

November 3, 2020
Manufacturing and Production, Research and Development Regeneron, clinical trials, garetosmab, pharma

Regeneron has slammed the brakes on its Phase 1 trial of garetosmab in the treatment of the ultra-rare condition fibrodysplasia …

News

UCB Pharma’s bimekizumab improves skin clearance over Humira in plaque psoriasis

November 3, 2020
Manufacturing and Production, Research and Development UCB Pharma, bimekizumab, pharma

In recent Phase 3 study data presented European Academy of Dermatology and Venereology Congress last weekend, UCB Pharma reported that …

News
covid_cell_1

T-cells respond to COVID-19 six months after infection

November 3, 2020
Manufacturing and Production

There is evidence that human T-cells can respond to coronavirus six months after the body is initially infected, according to …

News
800px-laboratoires_arkopharma_-_chaine_de_conditionnement_remplissage_piluliers_1

Novavax to expand Maryland facility to support global vaccine development

November 3, 2020
Manufacturing and Production

Novavax has announced that it plans to expand its Maryland campus to facilitate the company’s growth as it develops its …

News
tt

How the US election could affect the pharmaceutical industry

November 3, 2020
Manufacturing and Production

The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of …

News
800px-pfizer_finland_hq_february_13_2009_2

Pfizer announces €300m investment in Irish manufacturing sites

November 2, 2020
Sales and Marketing

Pfizer is set to invest €300 million in its three Irish manufacturing sites in Ringaskiddy, Dublin and Kildare.  The investment …

News
madrid_-_johnson__johnson_1

Johnson & Johnson to begin testing COVID-19 vaccine on adolescent patients

November 2, 2020
Sales and Marketing

Johnson & Johnson plans to start testing its COVID-19 vaccine candidate in adolescents between the age of 12 and 18.  …

News
The Gateway to Local Adoption Series

Latest content

Alto Neuroscience announces new patent for depression treatment

January 15, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026